September 28, 2026
The FDA classified Boston Scientific's Imager II catheter recall as its most serious designation due to a risk of the catheter tip degrading and detaching inside patients.
What happened
The Food and Drug Administration slapped a Class I label on Boston Scientific's recall of its Imager II angiographic catheters. The agency flagged a potential for the catheter tip to break down and separate, which can cause severe injury. The stock moved down just 0.1 percent on the day.
Why it matters
A Class I recall signals a situation where a device can cause serious injury or death, which can halt sales, lead to lawsuits, and require costly remediation. The complication is that a detached tip inside a blood vessel must be retrieved, often through emergency surgery. The recall touched roughly 100 billion dollars of market value, and the move, though small, was bigger than the stock's typical daily swing over the past three years.
The case against
A 0.1 percent drop suggests investors see minimal financial impact. The recall appears contained to a single catheter line, not a broader platform, so the hit to revenue is likely immaterial against the company's total sales.
What settles it
Whether the company halts active shipments of the device or only targets existing inventory, and if the issue appears in other Boston Scientific catheter lines.